Literature DB >> 15245369

Molecular basis of predisposition to develop type 1 diabetes mellitus in North Indians.

R Rani1, A Sood, R Goswami.   

Abstract

Type 1 diabetes (T1D) mellitus is a multifactorial autoimmune disease where more than 90% of insulin-producing pancreatic beta cells are destroyed before the clinical manifestations, warranting a need to identify the children predisposed to get the disease. Of the 20 genomic intervals implicated for the risk to develop T1D, the major histocompatibility complex (MHC) region on chromosome 6p21.31 (IDDM1) has been the major contributor, followed by 5' regulatory region of the insulin (INS) gene on chromosome 11p15.5 (IDDM2). MHC has a role in antigen presentation and IDDM2 has been shown to have a role in transcription of insulin in the thymus. Hence, alleles of human leukocyte antigen (HLA)-DRB1, DQB1, and insulin-linked variable number of tandem repeats (INS-VNTR) were studied in 110 T1D patients and 112 healthy controls using polymerase chain reaction and hybridization with sequence-specific oligonucleotide probes (PCR-SSOP) and PCR restriction fragment length polymorphism (PCR-RFLP), respectively. HLA-DRB1*0301 was significantly increased in the T1D patients along with associated DQB1*0201 followed by DRB1*0401 and DRB1*0405. DRB1*0701 was observed to be the most protective allele followed by DRB1*0403 and DRB1*0404. Although DQB1*0302 which is associated with both the protective and susceptible DR4 alleles was not significantly increased, heterozygous DQB1*0201, *0302 was significantly increased in the TID patients. Because INS-VNTR class I homozygosity was also significantly increased in the patients, simultaneous presence of DRB1*0301 along with homozygous INS-VNTR class I, gave a relative risk (RR) of 70.81. However, a similar analysis of DQB1*0201 and *0302 along with INS-VNTR alleles did not give such high RRs. Thus, the two independently assorting alleles at two loci i.e., DRB1*0301 and INS-VNTR class I, on two different chromosomes may have the potential to predict a prediabetic in North India.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15245369     DOI: 10.1111/j.1399-0039.2004.00246.x

Source DB:  PubMed          Journal:  Tissue Antigens        ISSN: 0001-2815


  7 in total

1.  Type 1 diabetes mellitus in India.

Authors:  Eesh Bhatia
Journal:  Curr Diab Rep       Date:  2012-06       Impact factor: 4.810

2.  HLA class II diversity in HIV-1 uninfected individuals from the placebo arm of the RV144 Thai vaccine efficacy trial.

Authors:  K M Baldwin; P K Ehrenberg; A Geretz; H A Prentice; S Nitayaphan; S Rerks-Ngarm; J Kaewkungwal; P Pitisuttithum; R J O'Connell; J H Kim; R Thomas
Journal:  Tissue Antigens       Date:  2015-02

3.  Approaches in type 1 diabetes research: A status report.

Authors:  Oindrila Raha; Subhankar Chowdhury; Samir Dasgupta; P Raychaudhuri; B N Sarkar; P Veer Raju; V R Rao
Journal:  Int J Diabetes Dev Ctries       Date:  2009-04

4.  The genetic heterogeneity of Arab populations as inferred from HLA genes.

Authors:  Abdelhafidh Hajjej; Wassim Y Almawi; Antonio Arnaiz-Villena; Lasmar Hattab; Slama Hmida
Journal:  PLoS One       Date:  2018-03-09       Impact factor: 3.240

Review 5.  HLA-G and the MHC Cusp Theory.

Authors:  Bruna Miglioranza Scavuzzi; Vincent van Drongelen; Joseph Holoshitz
Journal:  Front Immunol       Date:  2022-02-25       Impact factor: 7.561

6.  Interaction of vitamin D receptor with HLA DRB1 0301 in type 1 diabetes patients from North India.

Authors:  Neetu Israni; Ravinder Goswami; Avinash Kumar; Rajni Rani
Journal:  PLoS One       Date:  2009-12-02       Impact factor: 3.240

7.  HLA class II SNP interactions and the association with type 1 diabetes mellitus in Bengali speaking patients of Eastern India.

Authors:  Oindrila Raha; Biswanath Sarkar; Bhaskar V K S Lakkakula; Veerraju Pasumarthy; Sudhakar Godi; Subhankar Chowdhury; Pradip Raychaudhuri; Raghavendra Rao Vadlamudi
Journal:  J Biomed Sci       Date:  2013-02-27       Impact factor: 8.410

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.